AI & Machine Learning
Evolutionary Algorithms in Digital HealthcareWe specialise in developing technologies for the diagnosis and monitoring of Parkinson’s, Alzheimer’s and other neurodegenerative conditions. Our clinically-validated medical devices have been used in medical centres and clinical trials worldwide.
Introducing ClearSky MD
Who we are
ClearSky Medical Diagnostics began as a collaboration with specialists from Leeds General Infirmary, Heriot-Watt University and the University of York who provided clinical expertise and machine learning knowledge.
We’re led by Professor Stephen Smith, who has been hailed a ‘national lifesaver’ in recognition of his research into the diagnosis and treatment of Parkinson’s.
Innovative technology
Our Products
LID-Monitor
Monitoring side-effects of medication for Parkinson’s. LID-Monitor offers a safe, simple and unobtrusive way of monitoring dyskinesia in the home.
ND-Monitor
Differentiating between neurodegenerative conditions. Data gloves with positioning sensors are worn to monitor how people perform simple test-grasp tasks.
PD-Monitor
Confirming diagnosis of Parkinson’s disease. PD-Monitor assists specialists by measuring symptoms of Parkinson’s while patients undertake routine clinical tasks.
CF-Monitor
Objectively assessing visuo-spatial ability. Patients draw on a digitising tablet and their hesitations and differences in movements are measured and analysed by the evolutionary algorithms.
Latest Stories
Our News
SCOR Innovation Podcast: Interview with Professor Smith
ClearSky’s co-founder Professor Stephen Smith discusses disruptive healthcare technologies in neurodegenerative diseases in the latest SCOR Innovation Podcast.
ClearSky attends ADI 2022 London Conference
ClearSky Medical Diagnostics has attended and exhibited at the 35th Global Conference of Alzheimer’s Disease International in June 2022.
Partners Wanted to Accelerate Development of Mild Cognitive Impairment Diagnostic Device
ClearSky Medical Diagnostics has developed an intelligent medical device that can objectively diagnose mild cognitive impairment (MCI), a condition often suggested as an early stage of dementia.
SERVICES
We offer a range of consultancy services.
CLINCIAL STUDIES
We have a number of clinical studies underway.
Get in touch
To arrange a demonstration, meeting or for more information on ClearSky MD, please use the contact form below. Check out our privacy policy for the full story on how we protect and manage your submitted data.